Login
$LBRX
$42.99 -$0.02 (0.05%) Live

$LBRX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

Strengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer

13 Oct 2026 Form 4: Miller Joseph M, Chief Financial Officer

Granted 200,000 Emplopyee Stock Option (Right to Buy)

13 Oct 2026 Form 4: Kozauer Susan Gani, Chief Medical Officer

Granted 200,000 Emplopyee Stock Option (Right to Buy)

13 Oct 2026 SCHEDULE 13G/A
05 Oct 2026 EFFECT
01 Oct 2026 POS AM
01 Oct 2026 S-3ASR
24 Sep 2026 Form 3: Kozauer Susan Gani, Chief Medical Officer

No securities owned

15 Sep 2026 424B3
15 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

NEW YORK, September 15, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the mu...

14 Sep 2026 Form 3: Miller Joseph M, Chief Financial Officer

No securities owned

03 Sep 2026 424B3
03 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

NEW YORK, September 3, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the mul...

14 Aug 2026 SCHEDULE 13G/A
11 Aug 2026 424B3
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Announced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027

03 Aug 2026 Form 4: Deep Track Biotechnology Master Fund, Ltd., 10% owner and 2 others

Acquired 286,205 Pre-Funded Warrants (Right to Buy) (Open Market Purchase) ($10M)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support